Loading clinical trials...
Loading clinical trials...
An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors
Conditions
Interventions
Rebastinib
Carboplatin
Locations
9
United States
University of California San Francisco (UCSF)
San Francisco, California, United States
UCLA Medical Center
Santa Monica, California, United States
University of Chicago
Chicago, Illinois, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
The Ohio State University
Columbus, Ohio, United States
Start Date
January 2, 2019
Primary Completion Date
May 1, 2022
Completion Date
November 1, 2022
Last Updated
December 27, 2024
NCT06716138
NCT06307795
NCT05581004
NCT06974812
NCT06107686
NCT05205109
Lead Sponsor
Deciphera Pharmaceuticals, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions